Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
2024 · Science · 136 citations
https://doi.org/10.1126/science.adi5798
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
26
Papers
787
Citations
14
h-index
14
i10-index
Mark Noviski is an academic researcher from Nurix (United States). The author has contributed to research in topics: Chronic Lymphocytic Leukemia Research & Protein Degradation and Inhibitors & T-cell and B-cell Immunology. The author has an h-index of 14, co-authored 23 publications.
ORCID: 0000-0001-8072-1059Click to start Chat